Healthcare Triangle, Inc. Announces 1-for-249 Reverse Stock Split as Part of Nasdaq Compliance Plan
The Company expects that the reverse stock split, which was approved by the Company's stockholders in a special meeting of Stockholders held on February 26, 2025, will increase the price per share of the Company's common stock, and is part of the Company's strategy to regain compliance with the $1.00 minimum bid price requirement of the Nasdaq Capital Market.
At the effective time of the reverse stock split, each two hundred forty-nine (249) shares of the Company's issued and outstanding common stock will be automatically converted into one (1) issued and outstanding share of common stock without any change in the par value of $0.00001 per share or the total number of authorized shares. The reverse stock split will reduce the Company's number of shares outstanding common stock from approximately 1,452,124,283 shares to approximately 5,831,850 shares. No fractional shares of common stock will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to receive a fractional share will be rounded up at a participant level in lieu thereof.
Stockholders of record as of August 1st, 2025, will be receiving information regarding their share ownership following the reverse stock split from the Company's transfer agent, VStock Transfer, LLC. VStock Transfer can be reached at (212) 828 8436. Additional information about the reverse stock split can be found in the Company's definitive information statement on Schedule 14C, filed with the U.S. Securities and Exchange Commission (the 'SEC') on March 17, 2025, and available free of charge at the SEC's website sec.gov.
About Healthcare Triangle
Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz(TM) and DataEz(TM). HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. For more information, visit www.healthcaretriangle.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate.' The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report filed with the SEC on March 31, 2025, previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Investor Contact
1-800-617-9550
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
18 minutes ago
- Miami Herald
Why did stocks tumble this week?
The stock market had a tough week, with the S&P 500 and tech-stock-heavy Nasdaq retreating sharply on Thursday and Friday following a batch of concerning news on inflation, jobs, and tariffs. The S&P 500 fell 2.7% from an early-week high while the Nasdaq lost 3.9% of its value from its peak on Thursday. Here's why stocks retreated, and what could happen next. The stock market sell-off began in earnest following the Federal Reserve's controversial decision to keep interest rates at 4.25% to 4.5%. President Trump has advocated for Fed Chairman Jerome Powell to cut rates aggressively, recommending a 3% reduction. Related: Goldman Sachs revamps Fed interest rate cut forecast for 2025 Lower interest rates support stock prices because they increase household and business spending, fueling revenue and profit growth. Powell's reluctance to lower rates remains a headwind for stocks this year. Powell cited risks of tariffs driving inflation higher later this year and a "solid" economy for the decision to leave rates unchanged. Many viewed his hawkish tone during his press conference as an indication that rates may not get cut at the next meeting in September either. The decision drew the ire of President Donald Trump, who has previously called Chairman Powell "Mr. Too Late" and a "numbskull" for not already reducing interest rates. The President renewed his calls for Powell to resign following the Fed meeting. Despite White House pressure, the Fed's dual mandate targets low unemployment and inflation, which dictates its decisions on monetary policy. The Fed's mandate purposefully excludes political jawboning. Unfortunately, the Fed's dual goals are contradictory. While Fed rate cuts boost economic activity and lower unemployment, they increase inflation. The opposite is true when it raises rates. This dynamic often means that the Fed hesitates for fear of causing more economic problems than it solves. Unfortunately, that often means that the Fed falls behind the curve when setting interest rates at appropriate levels, forcing it to act more aggressively than it might otherwise because the economy has gotten too hot or cold. That chasing can lead to greater uncertainty, causing stock market volatility. The stock market's sell-off earlier in 2025 was primarily due to higher-than-expected import tariffs and the risk that they would boost inflation, zapping economic activity. Those worries fell when President Trump paused many tariffs on April 9, kickstarting a massive stock market rally that sent the S&P 500 and Nasdaq up over 28% and 38%, respectively. More Layoffs: Intel's recent layoffs take an unexpected turnWalmart makes more cuts customers won't likeLooking for a job? Job ads probably won't help you find one However, now that President Trump's tariff pause expired on August 1, he's announced new tariffs ranging from 10% to 41%, including a 35% tariff on Canada, up from 25%. Canada was our third-largest trading partner in 2024. The higher tariffs are problematic, given that they occur even as the impact of tariffs left in place earlier this year seems to be increasing inflation. The Personal Consumption Expenditures index showed inflation increased to 2.6% in June, up from 2.4% in May and 2.2% in April. The higher and faster inflation rises, the more likely business and household spending will shrink, dinging corporate revenue and earnings growth at publicly traded companies. The stock market was also hit by disappointing jobs data. Stocks perform best when the economy creates more jobs and wages grow, creating extra discretionary income. Related: Jobs report shocker resets Fed interest rate cut bets On Friday, the Bureau of Labor Statistics said the US economy only added 73,000 jobs in July, far fewer than the 100,000 expected and 147,000 in June. As a result, the unemployment rate increased to 4.24%, its highest level this cycle. Meanwhile, the Job Openings and Labor Turnover Survey (JOLTS) showed the number of open jobs fell to 7.4 million in June from 7.7 million in May. In case that wasn't concerning enough, Challenger, Gray & Christmas reported that US employers announced 62,075 layoffs in July, up 29% from June and 140% year over year. Stocks have had a remarkable rally, and it's not shocking that they might take a break. August is a notoriously weak month for stock market returns, and recent gains have lifted the S&P 500's forward price-to-earnings ratio, a key valuation measure, to lofty levels. According to FactSet, the S&P 500's forward P/E ratio was 22.4 on Friday, near the highs set in February before tariff announcements caused a sell-off, and up from about 19 in April, when stocks were near the lows. With valuation arguably rich and inflation and jobs uncertainty growing, stocks could experience more volatility than usual this month. Long-term investors are likely best off simply recognizing that pullbacks are common. According to Capital Group, a money manager with $2.2 trillion under management, the S&P 500 retreats 5% to 10% about once per year. Short-term investors may want to take a different approach, locking in recent gains and looking for lower entry points in the coming weeks. Related: Morgan Stanley resets S&P 500 target for 2026 The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
an hour ago
- Yahoo
Elon Musk Warns of Losing Tesla Control, Denies Personal Loans Tied To Shares
Elon Musk, the CEO of Tesla Inc. (NASDAQ:TSLA), has expressed concerns over potentially losing control of the electric vehicle giant due to the influence of activist shareholders. What Happened: Musk, who currently owns a 12.8% stake in Tesla, is apprehensive about being dethroned by shareholders who may not align with his vision for the company's future. He suggests that a 25% ownership stake would offer him adequate influence, while still leaving room for his possible removal. Musk's fears are rooted in past instances where shareholders voted in favor of a compensation package tied to the company's growth targets, only to be overruled by Delaware Chancery Court Judge Kathaleen McCormick. Earlier in January in a post on X, he shared that about 25 percent ownership stake would be enough "to be influential, but not so much that I can't be overturned.'Musk has the opportunity to acquire an additional 304 million shares, which would boost his voting control by roughly 4% post-tax. Also Read: Elon Musk Returns To Intense Work Schedule: 'Back To Working 7 Days a Week and Sleeping in the Office' In a recent statement on Friday on X, Musk affirmed that he has no personal loans against Tesla stock and reiterated his anxieties about being ousted by 'activist shareholders'. He expressed optimism that these concerns would be addressed at the forthcoming shareholders' are rumors that Musk may resign if his ownership stake is curtailed, akin to the limitations imposed on his pay package. Nonetheless, a majority of shareholders who endorsed Musk's pay package continue to support his leadership of Tesla's operations. Why It Matters: Musk's concerns highlight the potential power dynamics at play within Tesla's shareholder base. His potential loss of control could significantly impact the company's strategic direction, given his instrumental role in shaping Tesla's innovative trajectory. The upcoming shareholders' meeting will be a critical event, potentially determining the future of Musk's leadership at Tesla. Read Next Elon Musk Commits To Intense Focus on X/xAI and Tesla: 'Back To Spending 24/7 at Work, Sleeping in Conference/Server/Factory Rooms' Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? TESLA (TSLA): Free Stock Analysis Report This article Elon Musk Warns of Losing Tesla Control, Denies Personal Loans Tied To Shares originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
TransMedics Group, Inc. (TMDX): A Bull Case Theory
We came across a bullish thesis on TransMedics Group, Inc. on Global Equity Briefing's Substack by Ray Myers. In this article, we will summarize the bulls' thesis on TMDX. TransMedics Group, Inc.'s share was trading at $118.97 as of July 31st. TMDX's trailing and forward P/E were 59.75 and 62.11 respectively according to Yahoo Finance. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. TransMedics is revolutionizing the organ transplant ecosystem through its Organ Care System, a technology designed to keep organs warm, oxygenated, and viable far longer than traditional cold storage. By tackling key bottlenecks—organ degradation, low utilization rates, and logistical constraints—Organ Care System significantly extends transplant windows and boosts usage rates. Clinical trial data highlights its transformative potential: expanded criteria lungs and hearts saw utilization jump to 87% and 81%, respectively, while DCD heart use rose from 0% to 89%. TMDX monetizes this impact through a razor-and-blade model—selling Organ Care System consoles and high-margin, single-use consumables—while providing end-to-end services through its National Organ Care System Program, a SaaS-like Organs as a Service platform. With 21 private jets, 17 procurement hubs, and trained staff, TMDX handles organ retrieval, transport, and maintenance, positioning itself as a logistics powerhouse in the transplant chain. The opportunity is vast: U.S. underutilization alone represents a $400M+ annual consumables revenue potential, and TMDX currently serves just 3% of the $39B global market expected by 2034. Future growth catalysts include a kidney Organ Care System by 2029, entry into international markets via a $200M facility in Italy, and scaling the National Organ Care System Program globally. Financially, the company achieved profitability in 2024, posting $441M in revenue and positive operating cash flow, though free cash flow remains negative due to capex-heavy expansion. Trading at a P/E of 91, investor returns hinge on continued execution, EU rollout, and successful kidney platform launch. If goals are met, the stock could double by 2030, but slower expansion or margin compression may limit upside. Previously, we covered a on TransMedics Group, Inc. by Oliver | MMMT Wealth in May 2025, which highlighted warm perfusion technology, strong execution, and real-time flight data as revenue indicators. The company's stock appreciated ~24% since Q1 outperformance played out. Ray Myers shares a similar view but emphasizes the SaaS-like NOP model and global expansion potential. TransMedics Group, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held TMDX at the end of the first quarter which was 29 in the previous quarter. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
